Wakunaga takes Japanese quinolone case to Supreme Court
This article was originally published in Scrip
Wakunaga Pharmaceutical has taken its fight with fellow Japanese company Dainippon Sumitomo Pharma (DSP) to the Supreme Court. The small firm has appealed a recent Osaka High Court decision that rejected its claims against DSP in a long-running dispute over a terminated 1998 licensing deal for a quinolone antibacterial. DSP brought the High Court appeal following a 2007 district court decision ordering it to pay ¥890 million ($8.9 million) in damages to Wakunaga (scripnews.com, March 27th, 2009). Wakunaga first filed suit in 2004, claiming then that Dainippon (which merged with Sumitomo Pharma in 2005) had acted improperly.
You may also be interested in...
Partners say they are encouraged by new overall response data from early trials for the two drugs together in kidney and liver cancer, presented to ASCO.
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.